The role of passive immunization in HIV-positive patients - A case report
Apstrakt
An HIV positive patient presented with pulmonary tuberculosis as her AIDS-defining diagnosis in 1993 and was effectively treated with 12 months of standard antituberculosis medications (isoniazide, rifampin, and pyrazinamide for 2 months). She received zidovudine for 6 weeks at the time of her diagnosis; however, because of patient preference, she has not received subsequent standard HIV medications (7 years). Her CD4 count at the time of diagnosis (1993) was 297/muL. Monthly passive immunotherapy was administered (fresh frozen plasma from HIV-negative blood donors with a significant titer for the anti-vasoactive intestinal peptide [VIP]/NTM antibody) from December 1993 to June 1994. Her CD4 count increased to GT 400/muL during the passive immunotherapy and has remained stable for the past 6 years. The rational for the use of anti-VIP/NTM antibodies preparations in HIV, the possible mode of action of anti-VIP/NTM antibodies, the use of Ig preparations, and the role of exercise as a nat...ural source of anti-VIP/NTM antibodies are discussed. This case report supports the potential therapeutic use of anti-VIP antibodies for treatment of HIV disease.
Ključne reči:
aerobic exercise / AIDS / anti-vasoactive intestinal peptide/NTM antibodies / HIV / Ig preparations / passive immunization / tuberculosisIzvor:
Chest, 2001, 120, 2, 662-666
DOI: 10.1378/chest.120.2.662
ISSN: 0012-3692
PubMed: 11502675
WoS: 000170405500056
Scopus: 2-s2.0-0034837728
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Veljković, Veljko AU - Metlaš, Radmila AU - Jevtović, D. AU - Stringer, WW PY - 2001 UR - https://vinar.vin.bg.ac.rs/handle/123456789/2448 AB - An HIV positive patient presented with pulmonary tuberculosis as her AIDS-defining diagnosis in 1993 and was effectively treated with 12 months of standard antituberculosis medications (isoniazide, rifampin, and pyrazinamide for 2 months). She received zidovudine for 6 weeks at the time of her diagnosis; however, because of patient preference, she has not received subsequent standard HIV medications (7 years). Her CD4 count at the time of diagnosis (1993) was 297/muL. Monthly passive immunotherapy was administered (fresh frozen plasma from HIV-negative blood donors with a significant titer for the anti-vasoactive intestinal peptide [VIP]/NTM antibody) from December 1993 to June 1994. Her CD4 count increased to GT 400/muL during the passive immunotherapy and has remained stable for the past 6 years. The rational for the use of anti-VIP/NTM antibodies preparations in HIV, the possible mode of action of anti-VIP/NTM antibodies, the use of Ig preparations, and the role of exercise as a natural source of anti-VIP/NTM antibodies are discussed. This case report supports the potential therapeutic use of anti-VIP antibodies for treatment of HIV disease. T2 - Chest T1 - The role of passive immunization in HIV-positive patients - A case report VL - 120 IS - 2 SP - 662 EP - 666 DO - 10.1378/chest.120.2.662 ER -
@article{ author = "Veljković, Veljko and Metlaš, Radmila and Jevtović, D. and Stringer, WW", year = "2001", abstract = "An HIV positive patient presented with pulmonary tuberculosis as her AIDS-defining diagnosis in 1993 and was effectively treated with 12 months of standard antituberculosis medications (isoniazide, rifampin, and pyrazinamide for 2 months). She received zidovudine for 6 weeks at the time of her diagnosis; however, because of patient preference, she has not received subsequent standard HIV medications (7 years). Her CD4 count at the time of diagnosis (1993) was 297/muL. Monthly passive immunotherapy was administered (fresh frozen plasma from HIV-negative blood donors with a significant titer for the anti-vasoactive intestinal peptide [VIP]/NTM antibody) from December 1993 to June 1994. Her CD4 count increased to GT 400/muL during the passive immunotherapy and has remained stable for the past 6 years. The rational for the use of anti-VIP/NTM antibodies preparations in HIV, the possible mode of action of anti-VIP/NTM antibodies, the use of Ig preparations, and the role of exercise as a natural source of anti-VIP/NTM antibodies are discussed. This case report supports the potential therapeutic use of anti-VIP antibodies for treatment of HIV disease.", journal = "Chest", title = "The role of passive immunization in HIV-positive patients - A case report", volume = "120", number = "2", pages = "662-666", doi = "10.1378/chest.120.2.662" }
Veljković, V., Metlaš, R., Jevtović, D.,& Stringer, W.. (2001). The role of passive immunization in HIV-positive patients - A case report. in Chest, 120(2), 662-666. https://doi.org/10.1378/chest.120.2.662
Veljković V, Metlaš R, Jevtović D, Stringer W. The role of passive immunization in HIV-positive patients - A case report. in Chest. 2001;120(2):662-666. doi:10.1378/chest.120.2.662 .
Veljković, Veljko, Metlaš, Radmila, Jevtović, D., Stringer, WW, "The role of passive immunization in HIV-positive patients - A case report" in Chest, 120, no. 2 (2001):662-666, https://doi.org/10.1378/chest.120.2.662 . .